CODX קפיטליזציה חשבונאית Co-Diagnostics

The development of new rapid testing systems for home and clinic use is proceeding as planned, ensuring a steady stream of R&D solutions for Co-Diagnostics, Inc. (CODX). Efficient international delivery of diagnostic kits to infection hotspots supports high business margins. Market price action, where the indicator stands at 0.02, confirms the status of a global leader in PCR testing, whose authority is based on impeccable accuracy and testing speed.

Book value capitalization reflects the issuer's net asset value minus all liabilities, serving as a measure of real capital. Analyzing the organization's book capital allows for the rapid identification of resource depreciation, which is critical for Co-Diagnostics, Inc. (CODX), whose stability is supported by optimizing logistics through third-party operators that minimize capital expenditures on transport and reduce the risk of operational dependency.